[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336301-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336301-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zebrafish-avatars-toward-functional-precision-medicine-in-low-grade-serous-ovarian-cancer","Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer","","Functional precision medicine aims to guide therapy by exposing patient-derived tissues directly to drugs. This study develops an in vivo zebrafish embryo model for low-grade serous ovarian cancer (LGSOC) and benchmarks responses against previously observed mouse PDX, cell line, and 3D tumor model data. A KRAS-mutant patient-derived LGSOC cell line was fluorescently injected into embryos, then xenograft size was assessed before random treatment allocation with trametinib, luminespib, or both. Tumor apoptosis and proliferation were quantified by confocal imaging, showing compact masses with Ki67-positive growth. Zebrafish xenografts responded to single-agent and combined targeted therapy within two weeks, supporting rapid complementary evaluation of targeted drugs in LGSOC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zebrafish-avatars-toward-functional-precision-medicine-in-low-grade-serous-ovarian-cancer/336301/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zebrafish-avatars-toward-functional-precision-medicine-in-low-grade-serous-ovarian-cancer/336301.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the goal of this study on low-grade serous ovarian cancer?","Question",{"text":63,"@type":64},"The study aims to establish an in vivo zebrafish embryo model for LGSOC and compare treatment responses with results from existing mouse, cell line, and 3D tumor models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were tumor cells introduced and treated in the zebrafish model?",{"text":68,"@type":64},"Fluorescently labeled, patient-derived KRAS-mutant LGSOC cells were injected into the perivitelline space of 2-day post-fertilization embryos. Xenografts were assessed at 1 day post-injection and then randomly assigned to trametinib, luminespib, or the combination for five days.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were measured to evaluate drug response?",{"text":72,"@type":64},"Tumor growth and tumor cell death were assessed. Confocal microscopy was used to analyze apoptosis and proliferation after treatment, and combined therapy amplified the positive tumor response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336301,1790618129,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","cancers   \nArticle  \nZebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer  \nCharlotte Fieuws 1,2,3, Jan Willem Bek 1,2,3, Bram Parton 1,2,3, Elyne De Neef 1,2,3, Olivier De Wever 3,4, Milena Hoorne 3,5, Marta F. Estrada 6, Jo Van Dorpe 3,7, Hannelore Denys 3,5, Koen Van de Vijver 3,7 and Kathleen B. M. Claes 1,2,3, *  \nCitation: Fieuws, C.; Bek, J.W.; Parton, B.; De Neef, E.; De Wever, O.; Hoorne, M.; Estrada, M.F.; Van Dorpe, J.; Denys, H.; Van de Vijver, K.; et al. Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer. Cancers 2024, 16, 1812. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16101812  \nAcademic Editor: Maria Barbolina  \nReceived: 20 March 2024  \nRevised: 30 April 2024  \nAccepted: 4 May 2024  \nPublished: 9 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium;  \ncharlotte.fieuws@ugent.be (C.F.); janwillem.bek@ugent.be (J.W.B.); bram.parton@ugent.be (B.P.)  \n2 Center for Medical Genetics Ghent, Ghent University Hospital, 9000 Ghent, Belgium  \n3 Cancer Research Institute Ghent, 9000 Ghent, Belgium; [olivier.dewever@ugent.be](olivier.dewever@ugent.be) (O.D.W.); [milena.hoorne@uzgent.be](milena.hoorne@uzgent.be) (M.H.); [jo.vandorpe@uzgent.be](jo.vandorpe@uzgent.be) (J.V.D.); [hannelore.denys@uzgent.be](hannelore.denys@uzgent.be) (H.D.); [koen.vandevijver@uzgent.be](koen.vandevijver@uzgent.be) (K.V.d.V.)  \n4 Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium  \n5 Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium  \n6 Champalimaud Centre of the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal; [marta.estrada@research.fchampalimaud.org](marta.estrada@research.fchampalimaud.org)  \n7 Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium  \n* Correspondence: [kathleen.claes@ugent.be](kathleen.claes@ugent.be)  \nSimple Summary: Selecting and developing effective therapies for distinct epithelial ovarian cancer subtypes necessitates tumor models that accurately recapitulate the individual characteristics and microenvironmental interactions. Patient-derived tumor models offer a promising approach by preserving the tumor’s integrity, providing a platform for personalized treatment strategies. Zebrafish embryos could be a useful tool for quickly testing potential treatments in parallel. In this research article, we aimed to evaluate the model using a real-world case study and compare results with existing in vitro and in vivo models. A patient-derived cell line from a low-grade serous ovarian cancer with a KRAS mutation was engrafted in zebrafish embryos. Xenografts were assigned to a five-day treatment with trametinib and/or luminespib, targeting two complementary pathways that have previously shown efficacy in other cancer models of this cell line. The zebrafish model offers several options to analyze the response of the tumor to drug exposure. Here, we evaluated both cell growth and cell death, which showed a significant positive tumor response upon treatment that was amplified further by combining the drugs.  \nAbstract: Ovarian cancer (OC) is an umbrella term for cancerous malignancies affecting the ovaries, yet treatment options for all subtypes are predominantly derived from high-grade serous ovarian cancer, the largest subgroup. The concept of \"functional precision medicine\" involves gaining personalized insights on therapy choice, based on direct exposure of patient tissues to drugs. This espe","cbCaikgucMYxgLZj","https://ap.wps.com/l/cbCaikgucMYxgLZj","pdf",1159614,13,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the goal of this study on low-grade serous ovarian cancer?\",\"answer\":\"The study aims to establish an in vivo zebrafish embryo model for LGSOC and compare treatment responses with results from existing mouse, cell line, and 3D tumor models.\"},{\"question\":\"How were tumor cells introduced and treated in the zebrafish model?\",\"answer\":\"Fluorescently labeled, patient-derived KRAS-mutant LGSOC cells were injected into the perivitelline space of 2-day post-fertilization embryos. Xenografts were assessed at 1 day post-injection and then randomly assigned to trametinib, luminespib, or the combination for five days.\"},{\"question\":\"What outcomes were measured to evaluate drug response?\",\"answer\":\"Tumor growth and tumor cell death were assessed. Confocal microscopy was used to analyze apoptosis and proliferation after treatment, and combined therapy amplified the positive tumor response.\"}]","Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer | PDF",1790014472,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03e1dea011da60898abb86052a02f529.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/360f50ca5d5b84ae0534b2421438470c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad52dbaf4c7822afcd82a6ebd7328f76.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d07bae17bb755d81777c2cf27d22ae3.webp",980,1385]